Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus subtilis DSM32444
- Development stage
- Phase 2
- Lead developer
- SporeGen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal, Oral (in Foods/supplements)[4]
01
Overview
Bacillus subtilis DSM32444 is a probiotic and postbiotic drug product derived from a specific strain of Bacillus subtilis, developed for use in both humans and animals[3][4][6]. It is used as a sterile inactive spore preparation (postbiotic) delivered mainly by intranasal administration for respiratory health, including prevention or treatment of viral respiratory infections like influenza and respiratory syncytial virus[2][6][7]. Its mechanism of action is thought to involve induction of innate immunity in the respiratory tract, anti-inflammatory effects, and competitive exclusion of pathogenic microbes; it does not require live spores for efficacy as the inactivated spore is non-replicative but retains immunogenic and safety characteristics[2][6][7]. The strain holds GRAS (Generally Recognized As Safe) status for human consumption, supported by FDA certification and multiple safety studies in rodents and humans[4][3][7].
- Brand names
- SPEROVID
- Other names
- Bacillus subtilis DSM32444KBacillus subtilis DSM 32444Bacillus subtilis strain DSM32444
Beyond the preview
Go deeper on Bacillus subtilis DSM32444.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus subtilis DSM32444.